Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a phone app slow kidney disease? new trial aims to find out

NCT ID NCT07561957

First seen Jun 24, 2026 · Last updated Jun 24, 2026

Summary

This study tests whether a smartphone app can help people with chronic kidney disease (CKD) follow the latest KDIGO treatment guidelines. Researchers will enroll 80 adults aged 16-30 with CKD who own a smartphone. The app provides reminders, education, and care recommendations to both patients and doctors. The goal is to see if using the app improves adherence to guidelines, which could delay kidney disease progression and reduce complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • St. James's Hospital

    RECRUITING

    Dublin, Ireland

  • Trinity College Dublin

    RECRUITING

    Dublin, Ireland

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

smartphone application

What this could lead to

If successful, this app could help kidney disease patients better follow treatment guidelines, potentially slowing disease progression and reducing complications.

What could go wrong

This is a small, early-stage study with only 80 participants, so results may not apply to everyone. The app's impact on actual health outcomes is uncertain.

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome congenital anomaly of kidney and urinary tract kidney disorder nephrotic syndrome proteinuria tuberous sclerosis tuberous sclerosis 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.